Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI).
Itziar de RojasJ RomeroO Rodríguez-GomezP PesiniA SanabriaA Pérez-CordonC AbdelnourI HernándezM Rosende-RocaA MauleónL VargasM AlegretA EspinosaG OrtegaS GilM GuitartA GailhajanetM A Santos-SantosSonia Moreno-GrauO Sotolongo-GrauS RuizL MontrrealE MartínE PelejàF LomeñaF CamposA VivasM Gómez-ChiariM A TejeroJ GiménezV Pérez-GrijalbaG M MarquiéG Monté-RubioS ValeroA OrellanaL TárragaM SarasaAgustin RuizM Boadanull nullPublished in: Alzheimer's research & therapy (2018)
Brain and plasma Aβ levels are partially correlated in individuals diagnosed with SCD. Aβ plasma measurements, particularly the TP42/40 ratio, could generate a new recruitment strategy independent of the APOE genotype that would improve identification of SCD subjects with brain amyloidosis and reduce the rate of screening failures in preclinical AD studies. Independent replication of these findings is warranted.
Keyphrases
- cognitive decline
- resting state
- white matter
- mild cognitive impairment
- functional connectivity
- computed tomography
- multiple sclerosis
- quality improvement
- positron emission tomography
- high fat diet
- angiotensin ii
- cell therapy
- adipose tissue
- bone marrow
- multiple myeloma
- skeletal muscle
- blood brain barrier
- bioinformatics analysis
- sleep quality